Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
Posted: February 25, 2025 at 2:45 am
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Link:
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
Posted in Global News Feed
Comments Off on Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
Myriad Genetics Announces Senior Leadership Transition
Posted: February 25, 2025 at 2:45 am
Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025
Read more:
Myriad Genetics Announces Senior Leadership Transition
Posted in Global News Feed
Comments Off on Myriad Genetics Announces Senior Leadership Transition
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Posted: February 25, 2025 at 2:45 am
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:
Read this article:
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Posted in Global News Feed
Comments Off on Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Cardiff Oncology to Present at Upcoming Investor Conferences
Posted: February 25, 2025 at 2:45 am
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences.
View original post here:
Cardiff Oncology to Present at Upcoming Investor Conferences
Posted in Global News Feed
Comments Off on Cardiff Oncology to Present at Upcoming Investor Conferences
XOMA Royalty to Present at Investor Conferences in March
Posted: February 25, 2025 at 2:45 am
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings.
Link:
XOMA Royalty to Present at Investor Conferences in March
Posted in Global News Feed
Comments Off on XOMA Royalty to Present at Investor Conferences in March
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Posted: February 25, 2025 at 2:45 am
Seasoned public company CFO with 25 years of leadership experience in biotech Seasoned public company CFO with 25 years of leadership experience in biotech
Excerpt from:
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Posted in Global News Feed
Comments Off on Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Revolution Medicines to Participate in March 2025 Investor Conferences
Posted: February 25, 2025 at 2:45 am
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in three upcoming investor conferences.
Follow this link:
Revolution Medicines to Participate in March 2025 Investor Conferences
Posted in Global News Feed
Comments Off on Revolution Medicines to Participate in March 2025 Investor Conferences
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
Posted: February 25, 2025 at 2:45 am
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024.
Posted in Global News Feed
Comments Off on Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the…
Posted: February 25, 2025 at 2:45 am
Highlights
Read the original post:
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the...
Posted in Global News Feed
Comments Off on Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the…
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
Posted: February 25, 2025 at 2:45 am
SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 45th Annual Health Care Conference at 3:10 p.m. ET on Monday, March 3, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
Read more:
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
Posted in Global News Feed
Comments Off on Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
